… to overcome EGFR TKI resistance induced by abnormal PI3K pathway activation. According
to OrigiMed NGS data, we found that PI3K pathway alterations represent 14.9% in EGFR TKI …

… that EGFR pathways take on cancers, EGFR TKIs that bind the tyrosine kinase domain of
EGFR … PIK3CA mutation-drived abnormal activation of PI3K pathway. 3. BRAF mutation-drived …

… EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR… clones existed prior to
EGFR-TKIs therapy and were selected … of EGFR-TKIs may involve HER3-PI3K/AKT signaling by …

… inhibition of PI3K/AKT pathway may effectively … EGFR-TKIs resistance induced by HGF
in EGFR mutant lung cancer. We, therefore, assessed whether bufalin combined with EGFR-TKIs …

… showed that Akt, a key downstream molecule of the PI3K pathway, was constitutively active
in PC9/ER and HCC827/ER cells. The important role of PI3K/Akt signaling pathway in the …

… of PI3K/Akt pathway by PI3K inhibitor and gefitinib could overcome HGF-mediated resistance
to EGFR-TKIs … inhibition of PI3K signaling pathway could overcome EGFR-TKI resistance …

… This review discusses the preclinical data supporting PI3K/Akt/mTOR pathway inhibitor
combinations in EGFR TKI-resistant NSCLC from the perspective of the various agents currently …

… receptor (EGFR) and their use as predictive biomarkers to tailor patient treatment with EGFR
tyrosine kinase inhibitors (TKIs) has revolutionized therapy of patients with advanced EGFR-…

… toward EGFR-TKI are through reactivation of PI3K-AKT and … the EGFR-TKI sensitivity in
harbored EGFR mutation NSCLC. … in EGFR TKI resistance lung cancer after EGFR-TKI therapy …

… with EGFR mutations have PI3K-AKT-mTOR and MEK-ERK under the sole regulation of EGFR,
and when treated with an EGFR TKI… PI3K pathway inhibitors will not be effective for EGFR-…